Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa (AURORA)

PHASE2CompletedINTERVENTIONAL
Enrollment

435

Participants

Timeline

Start Date

December 21, 2018

Primary Completion Date

January 14, 2021

Study Completion Date

March 9, 2021

Conditions
Hidradenitis SuppurativaAcne Inversa
Interventions
DRUG

Avacopan

Active treatment

OTHER

Placebo

Placebo

Trial Locations (91)

10012

Clinical Site, New York

14623

Clinical Site, Rochester

17033

Clinical Site, Hershey

19026

Clinical Site, Drexel Hill

19104

Clinical Site, Philadelphia

20774

Clinical Site, Largo

26505

Clinical Site, Morgantown

27516

Clinical Site, Chapel Hill

28209

Clinical Site, Charlotte

28277

Clinical Site, Charlotte

28401

Clinical Site, Wilmington

29407

Clinical Site, Charleston

30060

Clinical Site, Marietta

30263

Clinical Site, Newnan

30322

Clinical Site, Atlanta

30328

Clinical Site, Sandy Springs

32819

Clinical Site, Orlando

33016

Clinical Site, Hialeah

33021

Clinical Site, Hollywood

33028

Clinical Site, Pembroke Pines

33030

Clinical Site, Homestead

33125

Clinical Site, Miami

33144

Clinical Site, Miami

33173

Clinical Site, Miami

33327

Clinical Site, Weston

33486

Clinical Site, Boca Raton

33603

Clinical Site, Tampa

33614

Clinical Site, Tampa

33624

Clinical Site, Tampa

33765

Clinical Site, Clearwater

34470

Clinical Site, Ocala

35233

Clinical Site, Birmingham

35244

Clinical Site, Birmingham

36608

Clinical Site, Mobile

37215

Clinical Site, Nashville

40217

Clinical Site, Louisville

43209

Clinical Site, Bexley

43302

Clinical Site, Marion

44106

Clinical Site, Cleveland

45040

Clinical Site, Mason

45701

Clinical Site, Athens

46250

Clinical Site, Indianapolis

46307

Clinical Site, Crown Point

47715

Clinical Site, Evansville

48059

Clinical Site, Fort Gratiot

48084

Clinical Site, Troy

48346

Clinical Site, Clarkston

49085

Clinical Site, Saint Joseph

55455

Clinical Site, Minneapolis

60077

Clinical Site, Skokie

60640

Clinical Site, Skokie

63110

Clinical Site, St Louis

68144

Clinical Site, Omaha

70006

Clinical Site, Metairie

70124

Clinical Site, New Orleans

72758

Clinical Site, Rogers

72916

Clinical Site, Fort Smith

73071

Clinical Site, Norman

75231

Clinical Site, Dallas

77027

Clinical Site, Sugar Land

77054

Clinical Site, Houston

77056

Clinical Site, Houston

77084

Clinical Site, Houston

78218

Clinical Site, San Antonio

78660

Clinical Site, Austin

78745

Clinical Site, Austin

83713

Clinical Site, Boise

85006

Clinical Site, Phoenix

85255

Clinical Site, Scottsdale

90025

Clinical Site, Los Angeles

90045

Clinical Site, Los Angeles

90057

Clinical Site, Los Angeles

90266

Clinical Site, Manhattan Beach

90301

Clinical Site, Inglewood

91320

Clinical Site, Thousand Oaks

91324

Clinical Site, Northridge

92647

Clinical Site, Huntington Beach

92660

Clinical Site, Newport Beach

92708

Clinical Site, Fountain Valley

92821

Clinical Site, Fullerton

94063

Clinical Site, Redwood City

94538

Clinical Site, Fremont

94598

Clinical Site, Walnut Creek

Clinical Site, Quincy

97210

Clinical Site, Portland

99202

Clinical Site, Spokane

01915

Clinical Site, Beverly

02101

Clinical Site, Boston

07044

Clinical Site, Verona

028277

Clinical Site, Charlotte

02886

Clinical Site, Warwick

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY

NCT03852472 - Evaluation of Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa (AURORA) | Biotech Hunter | Biotech Hunter